<SEC-DOCUMENT>0001144204-16-104836.txt : 20160525
<SEC-HEADER>0001144204-16-104836.hdr.sgml : 20160525
<ACCEPTANCE-DATETIME>20160525165641
ACCESSION NUMBER:		0001144204-16-104836
CONFORMED SUBMISSION TYPE:	8-K
PUBLIC DOCUMENT COUNT:		3
CONFORMED PERIOD OF REPORT:	20160524
ITEM INFORMATION:		Submission of Matters to a Vote of Security Holders
ITEM INFORMATION:		Other Events
ITEM INFORMATION:		Financial Statements and Exhibits
FILED AS OF DATE:		20160525
DATE AS OF CHANGE:		20160525

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			AYTU BIOSCIENCE, INC
		CENTRAL INDEX KEY:			0001385818
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		IRS NUMBER:				470883144
		STATE OF INCORPORATION:			CO
		FISCAL YEAR END:			0630

	FILING VALUES:
		FORM TYPE:		8-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	000-53121
		FILM NUMBER:		161675242

	BUSINESS ADDRESS:	
		STREET 1:		373 INVERNESS PARKWAY
		STREET 2:		SUITE 200
		CITY:			ENGLEWOOD
		STATE:			CO
		ZIP:			80112
		BUSINESS PHONE:		(720) 437-6580

	MAIL ADDRESS:	
		STREET 1:		373 INVERNESS PARKWAY
		STREET 2:		SUITE 200
		CITY:			ENGLEWOOD
		STATE:			CO
		ZIP:			80112

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	AYTU BIOSCIENCE, INC.
		DATE OF NAME CHANGE:	20150609

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	Rosewind CORP
		DATE OF NAME CHANGE:	20070110
</SEC-HEADER>
<DOCUMENT>
<TYPE>8-K
<SEQUENCE>1
<FILENAME>v440974_8k.htm
<DESCRIPTION>FORM 8-K
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="margin: 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>UNITED STATES</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>SECURITIES AND EXCHANGE COMMISSION</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>Washington, D.C. 20549</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; text-align: center; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>FORM 8-K</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; text-align: center; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>CURRENT REPORT</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>Pursuant to Section 13 or 15(d) of the</B><BR>
<B>Securities Exchange Act of 1934</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; text-align: center; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">Date of report (Date of earliest event reported):&nbsp;&nbsp;&nbsp;<U>May 24, 2016</U></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
<TR STYLE="vertical-align: bottom">
    <TD COLSPAN="3" STYLE="border-bottom: Black 1pt solid; text-align: center">AYTU BIOSCIENCE, INC.</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD COLSPAN="3" STYLE="text-align: center">(Exact Name of Registrant as Specified in Charter)</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="width: 35%; text-align: center">&nbsp;</TD>
    <TD STYLE="width: 30%; text-align: center">&nbsp;</TD>
    <TD STYLE="width: 35%; text-align: center">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="border-bottom: Black 1pt solid; text-align: center">Delaware</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: center">000-53121</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: center">47-0883144</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="text-align: center">(State or Other Jurisdiction<BR>
of Incorporation)</TD>
    <TD STYLE="text-align: center">(Commission<BR>
File Number)</TD>
    <TD STYLE="text-align: center">(IRS Employer<BR>
Identification No.)</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD COLSPAN="2" STYLE="border-bottom: Black 1pt solid; text-align: center">373 Inverness Parkway, Suite 206, Englewood, Colorado</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: center">80112</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD COLSPAN="2" STYLE="text-align: center">(Address of Principal Executive Offices)</TD>
    <TD STYLE="text-align: center">(Zip Code)</TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">Registrant&rsquo;s Telephone Number, Including
Area Code:&nbsp;&nbsp;&nbsp;<U>(720) 437-6580</U></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Check the appropriate box below if the
Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions
(<I>see</I> General Instruction A.2. below):</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Wingdings">&uml;</FONT></TD><TD>Written communications pursuant to Rule 425 under the
Securities Act (17 CFR 230.425)</TD>
</TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Wingdings">&uml;</FONT></TD><TD>Soliciting material pursuant to Rule 14a-12 under the
Exchange Act (17 CFR 240.14a-12)</TD>
</TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Wingdings">&uml;</FONT></TD><TD>Pre-commencement communications pursuant to Rule 14d-2(b)
under the Exchange Act (17 CFR 240.14d-2(b))</TD>
</TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Wingdings">&uml;</FONT></TD><TD>Pre-commencement communications pursuant to Rule 13e-4(c)
under the Exchange Act (17 CFR 240.13e-4(c))</TD>
</TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>


<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%">&nbsp;</TD><TD STYLE="width: 33%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0in"></TD><TD STYLE="width: 1in; text-align: left"><B>Item 5.07</B></TD><TD><B>Submission of Matters to a Vote of Security Holders.</B></TD>
</TR></TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">The 2016 annual meeting of stockholders
for Aytu BioScience, Inc. was held on May 24, 2016. Of the 22,446,481 shares outstanding on the record date for the meeting, a
total of 16,328,811 were present or represented at the meeting.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">At the meeting, our stockholders elected
four members to our board of directors as follows:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" ALIGN="CENTER" STYLE="font: 10pt Times New Roman, Times, Serif; width: 80%; border-collapse: collapse">
<TR STYLE="vertical-align: bottom">
    <TD STYLE="width: 31%; border: black 1pt solid; padding-right: 5.5pt; padding-left: 5.5pt; text-align: center">&nbsp;<B>Members</B></TD>
    <TD STYLE="width: 23%; border-top: black 1pt solid; border-right: black 1pt solid; border-bottom: black 1pt solid; padding-right: 5.5pt; padding-left: 5.5pt; text-align: center"><B>Number of Shares Voted For</B></TD>
    <TD STYLE="width: 23%; border-top: black 1pt solid; border-right: black 1pt solid; border-bottom: black 1pt solid">
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 5.5pt; text-align: center"><B>Number of </B></P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 5.5pt; text-align: center"><B>Shares Withheld </B></P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 5.5pt; text-align: center"><B>(Includes Abstentions)</B></P></TD>
    <TD STYLE="width: 23%; border-top: black 1pt solid; border-right: black 1pt solid; border-bottom: black 1pt solid; padding-right: 5.5pt; padding-left: 5.5pt; text-align: center"><B>Broker Non-Votes</B></TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="border-right: black 1pt solid; border-bottom: black 1pt solid; border-left: black 1pt solid; padding-right: 5.5pt; padding-left: 5.5pt">Joshua R. Disbrow</TD>
    <TD STYLE="border-right: black 1pt solid; border-bottom: black 1pt solid; padding-right: 5.5pt; padding-left: 5.5pt; text-align: center">9,788,447</TD>
    <TD STYLE="border-right: black 1pt solid; border-bottom: black 1pt solid; padding-right: 5.5pt; padding-left: 5.5pt; text-align: center">277,515</TD>
    <TD STYLE="border-right: black 1pt solid; border-bottom: black 1pt solid; padding-right: 5.5pt; padding-left: 5.5pt; text-align: center">6,262,849</TD></TR>
<TR>
    <TD STYLE="vertical-align: bottom; border-right: black 1pt solid; border-bottom: black 1pt solid; border-left: black 1pt solid; padding-right: 5.5pt; padding-left: 5.5pt">Jarrett T. Disbrow</TD>
    <TD STYLE="vertical-align: bottom; border-right: black 1pt solid; border-bottom: black 1pt solid; padding-right: 5.5pt; padding-left: 5.5pt; text-align: center">9,720,858</TD>
    <TD STYLE="vertical-align: bottom; border-right: black 1pt solid; border-bottom: black 1pt solid; padding-right: 5.5pt; padding-left: 5.5pt; text-align: center">345,104</TD>
    <TD STYLE="vertical-align: top; border-right: black 1pt solid; border-bottom: black 1pt solid; text-align: center">6,262,849</TD></TR>
<TR>
    <TD STYLE="vertical-align: bottom; border-right: black 1pt solid; border-bottom: black 1pt solid; border-left: black 1pt solid; padding-right: 5.5pt; padding-left: 5.5pt">Michael Macaluso</TD>
    <TD STYLE="vertical-align: bottom; border-right: black 1pt solid; border-bottom: black 1pt solid; padding-right: 5.5pt; padding-left: 5.5pt; text-align: center">9,232,597</TD>
    <TD STYLE="vertical-align: bottom; border-right: black 1pt solid; border-bottom: black 1pt solid; padding-right: 5.5pt; padding-left: 5.5pt; text-align: center">833,365</TD>
    <TD STYLE="vertical-align: top; border-right: black 1pt solid; border-bottom: black 1pt solid; text-align: center">6,262,849</TD></TR>
<TR>
    <TD STYLE="vertical-align: bottom; border-right: black 1pt solid; border-bottom: black 1pt solid; border-left: black 1pt solid; padding-right: 5.5pt; padding-left: 5.5pt">Carl C. Dockery</TD>
    <TD STYLE="vertical-align: bottom; border-right: black 1pt solid; border-bottom: black 1pt solid; padding-right: 5.5pt; padding-left: 5.5pt; text-align: center">9,348,418</TD>
    <TD STYLE="vertical-align: bottom; border-right: black 1pt solid; border-bottom: black 1pt solid; padding-right: 5.5pt; padding-left: 5.5pt; text-align: center">717,544</TD>
    <TD STYLE="vertical-align: top; border-right: black 1pt solid; border-bottom: black 1pt solid; text-align: center">6,262,849</TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">The election of directors was determined by a plurality of the
votes cast at the meeting, whereby the four nominees receiving the highest number of &ldquo;FOR&rdquo; votes were elected as directors.
Withheld votes and broker non-votes were not treated as votes cast, and therefore had no effect on the proposal to elect directors.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">At the meeting, our stockholders took the
following actions:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 27.5pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>Approved, by a majority of our outstanding common stock,
an amendment to our Certificate of Incorporation to reduce the number of authorized shares of common stock from 300,000,000 to
100,000,000. The vote for such approval was 15,748,848 shares for, 351,790 shares against, 228,173 shares abstaining, and 0 shares
of broker non-votes. The affirmative vote of the holders of a majority of the total outstanding shares of our common stock as
of the record date was necessary to approve the amendment to our Certificate of Incorporation to reduce our authorized shares
of common stock. Withheld votes and broker non-votes were not treated as votes cast, and therefore were effectively a vote against
this proposal. This was a routine matter so brokers could vote shares they held for the benefit of their customers;</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 27.5pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>Did not approve an amendment to our Certificate of
Incorporation to reduce the number of authorized shares of preferred stock from 50,000,000 to 10,000,000. The vote for such approval
was 9,917,927 shares for, 111,386 shares against, 36,649 shares abstaining, and 6,262,849 shares of broker non-votes. The affirmative
vote of the holders of a majority of the total outstanding shares of our common stock as of the record date was necessary to approve
the amendment to our Certificate of Incorporation to reduce our authorized shares of common stock. Withheld votes and broker non-votes
were not treated as votes cast, and therefore were effectively a vote against this proposal. This was not a routine matter so
brokers could not vote shares they held for the benefit of their customers;</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 27.5pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 27.5pt"></P>

<!-- Field: Page; Sequence: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%">&nbsp;</TD><TD STYLE="width: 33%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 27.5pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>Approved, by a majority of our outstanding capital
stock, an amendment to our Certificate of Incorporation to effect a reverse stock split at a ratio of any whole number between
1-for-4 and 1-for-12, as determined by the board of directors, at any time before November 24, 2016, if and as determined by the
board of directors. The vote for such approval was 15,239,461 shares for, 902,146 shares against, 187,204 shares abstaining, and
0 shares of broker non-votes. The affirmative vote of the holders of a majority of the total outstanding shares of our common
stock as of the record date was necessary to approve the reverse stock split. Withheld votes and broker non-votes were not treated
as votes cast, and therefore were effectively a vote against this proposal. This was a routine matter so brokers could vote shares
they held for the benefit of their customers;</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 27.5pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>Approved a non-binding advisory basis, the compensation
of our named executive officers for fiscal year 2015. The vote for such approval was 9,658,034 shares for, 310,722 shares against,
97,206 shares abstaining, and 6,262,849 shares of broker non-votes. The affirmative vote of the holders of a majority of the votes
cast at the meeting was necessary to approve the advisory vote on executive compensation. Withheld votes and broker non-votes
were not treated as votes cast, and therefore had no effect on this proposal;</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 27.5pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>Approved on a non-binding advisory basis, the frequency
with which future advisory votes on executive compensation should be held every third year. The shareholders were voting on either
one, two or three years for frequency with which future advisory votes on executive compensation should be held. The vote for
one year was 1,851,931 shares for, 264,316 shares for two years, 7,895,656 shares for three years, 54,059 shares abstaining and
6,262,849 shares of broker non-votes. A majority of the votes cast were for a non-binding approval of executive compensation every
three years. The advisory vote on the frequency of future votes on executive compensation was decided by a plurality of the votes
cast at the meeting whereby the frequency period (every one, two or three years) receiving the highest number of &ldquo;FOR&rdquo;
votes was selected. Withheld votes and broker non-votes were not treated as votes cast, and therefore had no effect on this proposal;
and</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 27.5pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>Ratified the appointment of EKS&amp;H, LLLP as our
independent registered public accounting firm for the fiscal year ending June 30, 2016. The vote for such approval was 15,879,835
shares for, 270,080 shares against, 178,896 shares abstaining, and 0 shares of broker non-votes. The affirmative vote of the holders
of a majority of the votes cast at the meeting was necessary to ratify the appointment of EKS&amp;H as our independent registered
public accounting firm. Withheld votes and broker non-votes were not treated as votes cast, and therefore had no effect on this
proposal.</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 27.5pt"><B>&nbsp;</B></P>


<!-- Field: Page; Sequence: 3 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%">&nbsp;</TD><TD STYLE="width: 33%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0in"></TD><TD STYLE="width: 1in; text-align: left"><B>Item 8.01</B></TD><TD><B>Other Events</B></TD>
</TR></TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">On May 25, 2016, we issued a press release
regarding the approval by our stockholders of an amendment to our Certificate of Incorporation to effect a reverse stock split
of our outstanding common shares at an exchange ratio of not less than 1-for-4 and not more than 1-for-12, as determined by the
board of directors at any time before November 24, 2016. A copy of the press release is attached as Exhibit 99.1 hereto and incorporated
herein by reference.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0in"></TD><TD STYLE="width: 1in; text-align: left"><B>Item 9.01.</B></TD><TD><B>Financial Statements and Exhibits.</B></TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in; text-align: left">(d)</TD><TD>Exhibits</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 1in"></TD><TD STYLE="width: 1in; text-align: left"><U>Exhibit No.</U></TD><TD><U>Description</U></TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 1in"></TD><TD STYLE="width: 1in; text-align: left">99.1</TD><TD>Press release dated May 25, 2016</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<!-- Field: Page; Sequence: 4 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%">&nbsp;</TD><TD STYLE="width: 33%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><U>SIGNATURE</U></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Pursuant to the requirements of the Securities
Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 50%">Date: May 25, 2016</TD>
    <TD STYLE="width: 35%">AYTU BIOSCIENCE, INC.</TD>
    <TD STYLE="width: 15%">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid">/s/ Gregory A. Gould</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>Name:&nbsp;&nbsp;Gregory A. Gould</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>Title:&nbsp;&nbsp;&nbsp;&nbsp;Chief Financial Officer</TD>
    <TD>&nbsp;</TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<!-- Field: Page; Sequence: 5 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%">&nbsp;</TD><TD STYLE="width: 33%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>2
<FILENAME>v440974_ex99-1.htm
<DESCRIPTION>EXHIBIT 99.1
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"><B>Exhibit 99.1</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><IMG SRC="image_001.jpg"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Aytu BioScience to Optimize Capitalization
in Support of Future Anticipated Uplisting of its Common Stock to a National Exchange</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><I>Shareholders </I>Authorize Board of Directors
to Effect a Reverse Split of the Company&rsquo;s Common Stock</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Englewood, CO &ndash; May 25, 2016 &ndash; </B>Aytu BioScience,
Inc. (OTCQX: AYTU), a specialty pharmaceutical company focused on global commercialization of novel products in the field of urology,
announced today that its shareholders voted to approve a proposal authorizing the Company&rsquo;s Board of Directors to amend Aytu&rsquo;s
certificate of incorporation to effect a reverse split of the Company&rsquo;s common stock, which is expected to enable Aytu to
meet the initial listing requirements of a national stock exchange.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Specifically, Aytu shareholders authorized the Board of Directors
to effect a reverse stock split of the Company&rsquo;s outstanding common shares at an exchange ratio of not less than 1-for-4
and not more than 1-for-12. The final ratio and timing will be determined by the Company&rsquo;s Board of Directors in relation
to Aytu&rsquo;s stock price, in an effort to retain maximum value for shareholders in advance of the planned uplisting. The changes
are expected to occur during the first half of fiscal 2017, which for Aytu corresponds to the six month period ended December 31,
2016, to be followed by the uplisting of Aytu&rsquo;s common stock onto one of the primary national exchanges.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Josh Disbrow, Chief Executive Officer of Aytu BioScience, Inc.,
stated, &ldquo;A key component of our capital markets strategy has been to uplist Aytu&rsquo;s stock to a national stock exchange
as quickly as possible, and in line with our overall growth. Having now built a robust portfolio of complementary urology products
with demonstrated revenue growth, preparing Aytu to list on a national exchange represents a significant step toward building long-term
shareholder value by increasing visibility, liquidity, and interest among a broader and more diverse shareholder base.&rdquo;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>About Aytu BioScience, Inc. </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Aytu BioScience is a commercial-stage specialty pharmaceutical
company focused on global commercialization of novel products in the field of urology. The company currently markets two products:
ProstaScint<SUP>&reg;</SUP> (capromab pendetide), the only FDA-approved imaging agent specific to prostate cancer, and Primsol<SUP>&reg;</SUP>
(trimethoprim hydrochloride), the only FDA-approved trimethoprim-only oral solution for urinary tract infections. Aytu recently
acquired exclusive U.S. rights to Natesto<SUP>&reg;</SUP>, the first and only FDA-approved nasal formulation of testosterone for
men with hypogonadism (low testosterone, or &ldquo;Low T&rdquo;), which the company plans to launch in July 2016. Additionally,
Aytu is developing MiOXSYS&trade;, a novel, rapid semen analysis system with the potential to become a standard of care for the
diagnosis and management of male infertility caused by oxidative stress. MiOXSYS is commercialized outside the U.S. where it is
a CE Marked, Health Canada cleared product, and Aytu is conducting U.S.-based clinical trials in pursuit of 510k <I>de novo</I>
medical device clearance by the FDA. Aytu&rsquo;s strategy is to continue building its portfolio of revenue-generating urology
products, leveraging its focused commercial team and expertise to build leading brands within well-established markets.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%">&nbsp;</TD><TD STYLE="width: 33%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><IMG SRC="image_001.jpg"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>For Investors &amp; Media:</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><U>Tiberend Strategic Advisors, Inc.</U></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Joshua Drumm, Ph.D.: jdrumm@tiberend.com; (212) 375-2664</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Janine McCargo: jmccargo@tiberend.com; (646) 604-5150</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Forward Looking Statement</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">This press release includes forward-looking statements within
the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, or
the Exchange Act. All statements other than statements of historical facts contained in this presentation, including statements
regarding our anticipated future clinical and regulatory events, future financial position, business strategy and plans and objectives
of management for future operations, are forward-looking statements. Forward looking statements are generally written in the future
tense and/or are preceded by words such as &ldquo;may,&rdquo; &ldquo;will,&rdquo; &ldquo;should,&rdquo; &ldquo;forecast,&rdquo;
&ldquo;could,&rdquo; &ldquo;expect,&rdquo; &ldquo;suggest,&rdquo; &ldquo;believe,&rdquo; &ldquo;estimate,&rdquo; &ldquo;continue,&rdquo;
&ldquo;anticipate,&rdquo; &ldquo;intend,&rdquo; &ldquo;plan,&rdquo; or similar words, or the negatives of such terms or other variations
on such terms or comparable terminology. These statements are just predictions and are subject to risks and uncertainties that
could cause the actual events or results to differ materially. These risks and uncertainties include, among others: the success
of the strategy to list the common stock on a national securities exchange, the potential future commercialization of our product
candidates, the anticipated start dates, durations and completion dates, as well as the potential future results, of our ongoing
and future clinical trials, the anticipated designs of our future clinical trials, anticipated future regulatory submissions and
events, risks relating to gaining market acceptance of our products, obtaining reimbursement by third-party payors, our anticipated
future cash position and future events under our current and potential future collaborations. We also refer you to the risks described
in &ldquo;Risk Factors&rdquo; in Part I, Item 1A of Aytu BioScience, Inc.&rsquo;s Annual Report on Form 10-K and in the other reports
and documents we file with the Securities and Exchange Commission from time to time.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<!-- Field: Page; Sequence: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%">&nbsp;</TD><TD STYLE="width: 33%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>3
<FILENAME>image_001.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 image_001.jpg
M_]C_X  02D9)1@ ! 0   0 !  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" !, +0# 2(  A$! Q$!_\0
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M26NC_F!:;_WT_P#C7F_C;Q<WC77/[7FTVVLKEHPDOD$XDQT8Y[XX_ 5]<_\
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M^A"NL_X7C\1?^@7:?^ ,G_Q5<A8:7XE\<>/H[UM+F^U7=VLT[) R1IR,GGH
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3S"=Q()&3ZD#BKU% !1110!__V0$!

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
